Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.

about

Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.

Item

http://www.wikidata.org/entity/Q54979386

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Trastuzumab upregulates PD-L1 ...... stimulation of IFNγ secretion.

@en

Trastuzumab upregulates PD-L1 ...... stimulation of IFNγ secretion.

@nl

type

Item

label

Trastuzumab upregulates PD-L1 ...... stimulation of IFNγ secretion.

@en

Trastuzumab upregulates PD-L1 ...... stimulation of IFNγ secretion.

@nl

prefLabel

Trastuzumab upregulates PD-L1 ...... stimulation of IFNγ secretion.

@en

Trastuzumab upregulates PD-L1 ...... stimulation of IFNγ secretion.

@nl

P1476

Trastuzumab upregulates PD-L1 ...... stimulation of IFNγ secretion.

@en

P2093

Anneliese Gest

http://www.w3.org/2001/XMLSchema#string

Bharat K R Chaganty

http://www.w3.org/2001/XMLSchema#string

Louis M Weiner

http://www.w3.org/2001/XMLSchema#string

Songbo Qiu

http://www.w3.org/2001/XMLSchema#string

Yang Lu

http://www.w3.org/2001/XMLSchema#string

Zhen Fan

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy

Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

New immunotherapies targeting the PD-1 pathway

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

P304

47-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CANLET.2018.05.009

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

430

http://www.w3.org/2001/XMLSchema#string

P50

Cristina Ivan

George A. Calin

P577

2018-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29746929

http://www.w3.org/2001/XMLSchema#string

P932

6004098

http://www.w3.org/2001/XMLSchema#string